Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03278535
Other study ID # NL61229.068.17
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 4, 2017
Est. completion date June 3, 2021

Study information

Verified date July 2021
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Three dimensional gait analysis is widely accepted as a general measure of functional ability among individuals as it is related to health, well-being and quality of life. To diagnose subtle changes/deviations in gait and to correctly interpret gait, a reference gait database of healthy subjects is required. Computer Assisted Rehabilitation Environment (Caren) is a new gait analysis system which combines the 3D motion captures system with a split belt force plate instrumented treadmill and a virtual reality environment. This system enables to analyses several successive steps, which is impossible in the standard overground laboratories. Until now, no reference gait database has been created using the Caren system. The aim of this descriptive study is to create a reference database of gait in healthy adults with varying subject characteristics using Caren. This study is a single center descriptive study to build a reference database on gait of healthy adults of different ages. Six age groups are composed existing of 20 males and 20 females. Taken into account that 10% of the volunteers (especially elderly) may drop out due to e.g. disability, a total of 264 subjects will be recruited to ensure that database will include 240 subjects. Inclusion criteria: ambulatory, ability to walk without aid for 30 minutes, age older than 18 years and willing to participate. Exclusion criteria: muscular skeletal, cardiopulmonary disorders or other diseases significantly influencing gait. Medical interventions, such as surgical treatment or botulinium toxin 6 months, which significantly influence gait. Subjects will walk at different walking speeds at Caren while gait is measured. Subjects always wear a safety harness to avoid falling. In addition adults wear standard shoes (gymnastic booties) provided by the lab to avoid shoes effects. All subjects undergo measurement of leg length, body length and body weight in order to retrieve anthropometric parameters. In addition a standard physical examination is performed to get information about a subjects' muscle strength, balance and articular mobility of the hip, knee and ankle. Gait kinematic, kinetic, spatio-temporal and balance parameters are measured.


Description:

Gait is one of the most important activity of daily life for humans. In clinical and research settings, gait performance is widely accepted as a general measure of functional ability among individuals. Computer Assisted Rehabilitation ENvironment (CAREN; Motek Medical, Amsterdam, The Netherlands) is a relatively novel system to analyze gait in a safe and accurate way. CAREN consists of an instrumented split-belt treadmill mounted onto a 6-degree-of-freedom motion platform in combination with a Virtual Environment projected on a 180° semi-cylindrical screen. Two force plates underneath each belt and 12 3D motion capture cameras (VICON system) allow an accurate analysis of gait which is expressed by kinematic, kinetic, spatiotemporal en dynamic balance parameters. Currently at the MUMC+, CAREN-based gait analysis is used for clinical purposes and is increasingly more applied to contribute in clinical diagnostics and decision-making and to evaluate interventions and rehabilitation programs. Besides, the CAREN system is applied in gait analysis laboratory settings as an alternative or an additive to over ground gait analysis. However, due to its novelty, size, high costs, and complexity, the CAREN system is not a widely accessible technology. Literature is limited and research is still in progress. From these experiences, it is known that CAREN is safe in use. An individuals' walking pattern is variable and can change due to several factors such as advancing age. Furthermore gait is influenced by body characteristics such sex, body height and mass. Gait also changes as a result of health-related factors such as pain and diseases. Moreover gait can change through rehabilitation and training. This all suggests that human gait analysis is useful for clinical purposes, for example for diagnostics or to evaluate rehabilitation programs. However to apply human gait analysis in clinical practice, it is crucial to have insight into the normal walking pattern of individuals. A gait database of healthy subjects with varying subject characteristics (e.g. age) is required to ensures that gait is correctly interpreted. This database will give further insight in the dynamics of walking, clarifying the level and proportion in which gait is affected by subject characteristics and walking speed. This insight will improve the interpretation of gait, and thus contribute to improved clinical diagnostics and follow up capabilities. In addition the database will be relevant in clinical practice as it quickly puts into perspective gait of patients. Moreover it enables the detection of subtle changes in gait (e.g. after intervention). Objective and hypothesis: This research is a single center descriptive study to create a reference database of gait of healthy adults of different ages. Six age groups are composed (18-29yrs, 30-39yrs, 40-49yrs, 50-59yrs, 60-69yrs, >70yrs), existing of 20 males and 20 females. This descriptive study aims to build a reference gait database for healthy subjects based on CAREN including kinematic, kinetic, spatio-temporal and balance parameters. Values for gait parameters of healthy adults will be created for varying age groups and sex. In addition, knowing the impact of walking speed on various gait parameters, gait parameters of healthy subjects will be clustered per walking speed, taking sex and age into account. Primary Objective: A descriptive study to collect a Caren-based reference database for healthy gait. Secondary Objectives: - To investigate effects of subject characteristics such as age, sex and leg length on gait kinematic, kinetic, temporal-spatial and balance parameters. - To investigate the relation between walking speed and gait kinematic, kinetic, temporal-spatial and balance parameters. Methods: This is a single center descriptive study performed at the department Physiotherapy of the Maastricht University Medical Center (MUMC+) in which gait of healthy adult volunteers of varying ages is obtained by the new Computer Assisted Rehabilitation ENvironment (Caren) system. The collected data will be used to create a database for gait parameters of healthy subjects. 120 healthy men and 120 healthy women, equally divided over the six age groups (18-29j, 30-39j, 40-49j, 50-59j, 60-69j, >70j) are included. The healthy adult volunteers will walk at different walking speeds at the Caren system. First, the comfortable walking speed of the subject is determined using a ramp protocol. This includes that subject starts walking at 0.5m/s and that the speed is increased every second by 0.01m/s until the subject reached the comfortable walking speed. This is repeated 3 times. The average of these 3 walking speeds is used as comfortable walking speed. Afterward, the subject walks for 5 minutes at the fixed comfortable speed to get familiarized to the system. After familiarization, the measurement starts. The volunteers will walk at comfortable speed, at a slow speed (comfortable speed - 30%), a fast speed (comfortable speed + 30%) and at a slower speed (fixed at 0.5km/h). These four conditions are randomly applied to eliminate a possible effect of sequence of performed walking speed (and thus familiarization) on gait. Every measurement is proceeded by a 2 minute habituation period at that specific walking speed. Subjects will wear a safety harness to avoid falling. In addition adults wear standard shoes (gymnastic booties) provided by the lab to avoid shoes effects. Gait kinematics (joint angles), kinetics (joint moments and power), spatio-temporal parameters (e.g. stride length) and dynamic balance parameters (e.g. margins of stability) will be determined. Values for gait parameters of healthy adults will be created and clustered for varying age groups, sex and walking speeds.


Recruitment information / eligibility

Status Completed
Enrollment 264
Est. completion date June 3, 2021
Est. primary completion date June 3, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Ambulatory - Ability to walk without aid for 30 minute - Willing to participate and able to provide informed consent. - 18 years or older Exclusion Criteria: - Muscular skeletal, cardiopulmonary disorders or other diseases significantly influencing gait. - Medical interventions, such as surgical treatment or botulinium toxin 6 months, which significantly influence gait.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
CAREN-based gait analysis
subjects only walk at CAREN at different speed

Locations

Country Name City State
Netherlands Maastricht UMC Maastricht Limburg

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary CAREN-based kinematic gait parameters Kinematics of the hip, knee and ankle measured during the gait cycle (e.g. stance phase knee flexion). 4-7-2017 until 3-6-2021
Primary CAREN-based kinetic gait parameters Kinetics of the hip, knee and ankle measured during the gait cycle (e.g. flexion/extension moments of the hip) 4-7-2017 until 3-6-2021
Primary CAREN-based spatiotemporal gait parameters e.g. walking speed, stride time, cadence, step width, step length. 4-7-2017 until 3-6-2021
Primary CAREN-based balance parameter mediolateral and backward margins of stability (MoS) 4-7-2017 until 3-6-2021
Secondary anthropometric characteristic: body height Body height (cm) 4-7-2017 until 3-6-2021
Secondary anthropometric characteristic: body weight Body weight (kg) 4-7-2017 until 3-6-2021
Secondary anthropometric characteristic: leg length Leg length (cm) 4-7-2017 until 3-6-2021
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1